Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride's impact on fertility is discussed, with users sharing experiences of conceiving while on the medication. Concerns about long-term safety are also mentioned.

Finasteride can increase total testosterone and potentially raise estrogen levels, leading to side effects. Biotin in combined tablets can falsely elevate thyroid hormone levels in blood tests.

The conversation discusses the use of 5-alpha-reductase inhibitors like finasteride and dutasteride for hair loss in transgender women, particularly in relation to testosterone suppression. The original poster has been using dutasteride and is considering stopping it due to undetectable testosterone levels.

The conversation discusses the idea of naturally lowering testosterone levels to potentially reduce DHT and help with hair loss, though it is speculative and not tested by the original poster. Participants suggest using treatments like finasteride, dutasteride, or RU58841 instead, as they directly target DHT without reducing testosterone.

Low-dose topical finasteride may reduce scalp DHT with fewer side effects than oral finasteride, though it can still lower blood serum DHT. Users report varying experiences, with some finding topical use effective and side-effect-free, while others note significant DHT suppression.

The conversation discusses the effectiveness of anti-androgens for hair loss, with a preference for topical treatments like RU58841 over oral options due to better scalp concentration and fewer side effects. Topical finasteride at 0.1% may provide some results, especially when combined with a topical androgen receptor antagonist like RU58841.

The user is concerned about high prolactin levels and low testosterone levels after stopping finasteride for three weeks. They are considering resuming finasteride but are worried it might further increase prolactin levels.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

The user suspects scarring alopecia and is exploring NSAIDs and turmeric/pepper for inflammation-related hair loss, having experienced burning and thinning with finasteride and testosterone reduction. They are seeking feedback while unable to afford a dermatologist.

Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

Teak leaf extract shows potential as a mild hair growth promoter for androgenic alopecia, with similar positive trends to minoxidil but without significant side effects. It can be made at home using dried teak leaves and ethanol, though its effectiveness compared to other treatments like finasteride is debated.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

The conversation discusses that dutasteride may be more effective than finasteride for frontal hair loss due to higher 5ar Type 1 enzyme activity in that area. Some users question the validity of this information, while others confirm it with additional sources.

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

Microneedling before applying topical finasteride or dutasteride may enhance their effectiveness by increasing local absorption in the scalp, despite concerns about systemic absorption. Users discuss combining this method with oral treatments and minoxidil, noting potential benefits and side effects.

Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.

Finasteride works by reducing DHT, which helps stop hair miniaturization. The user is on finasteride and believes it works due to its effect on growth factors and DHT reduction.

Finasteride raises total testosterone but lowers free testosterone, which is important for male health. Users report mixed experiences with their fitness levels and blood test results after using finasteride.

The user observed that stopping nicotine and caffeine improved their scalp health while using oral finasteride. However, relapsing with caffeine and nicotine caused scalp tightness and inflammation.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The user is using finasteride 1mg every other day and seeks a topical solution excluding minoxidil. They are considering various combinations of ingredients like finasteride, dutasteride, and tofacitinib, with options for nourishing oils and other additives.

User discusses Alfatradiol (17a-Estradiol) as a potential hair loss treatment with mixed results. Concerns include low dosage, receptor theory, and possible increased aromatase activity on scalp.

A 19-year-old transgender individual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.

Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.